1,120 reports of this reaction
5.5% of all BENDAMUSTINE HYDROCHLORIDE reports
#1 most reported adverse reaction
OFF LABEL USE is the #1 most commonly reported adverse reaction for BENDAMUSTINE HYDROCHLORIDE, manufactured by Cephalon, LLC. There are 1,120 FDA adverse event reports linking BENDAMUSTINE HYDROCHLORIDE to OFF LABEL USE. This represents approximately 5.5% of all 20,231 adverse event reports for this drug.
Patients taking BENDAMUSTINE HYDROCHLORIDE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among BENDAMUSTINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for BENDAMUSTINE HYDROCHLORIDE:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 1,120 FDA reports for BENDAMUSTINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 5.5% of all adverse event reports for BENDAMUSTINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience off label use while taking BENDAMUSTINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.